

Development Portfolio by Therapeutic Area

Listed below are our clinical studies and approved indications for our marketed products in the related therapeutic area as of February 5, 2026. Whether any of the listed compounds ultimately becomes a marketed product depends on the results of clinical studies, the competitive landscape of the potential product's market, reimbursement decisions by payers and the manufacturing processes necessary to produce the potential product on a commercial scale, among other factors. There can be no assurance that we will seek regulatory approval of any of these compounds or that, if such approval is sought, it will be obtained. There is also no assurance that a compound which gets approved will be commercially successful. At this stage of development, we cannot determine all intellectual property issues or all the patent protection that may, or may not, be available for these investigational compounds.



Hematology

Phase I

Investigational Compounds

BCL6 LDD

– Lymphoma

CD33-GSPT1 ADC

– AML

Dual Targeting

BCMAxGPC5D CAR T

– RRMM

HbF Activating CELMoD

– Sickle Cell Disease

mezigdomide +

elranatamab

– RRMM

Phase II

Additional Indications

REBLOZYL*

– α-Thalassemia

Investigational Compounds

arlo-cel

– 4L+ MM

golcadomide

– 1L FL

Phase III

Additional Indications

OPDIVO*

– 1L cHL

REBLOZYL*

– 1L NTD MDS Associated Anemia

– 1L TD MF Associated Anemia

Investigational Compounds

arlo-cel

– 2-4L MM

golcadomide

– 2L+ FL

– High Risk 1L LBCL

iberdomide

– 2L+ MM

– Post-Autologous Stem Cell Transplant Maintenance NDMM

mezigdomide

– 2L+ MM Kd

– 2L+ MM Vd

Approved Indications

ABECMA

– 3L+ Triple-Class Exposed RRMM

BREYANZI

– 2L+ LBCL

– 3L+ CLL/SLL

– 3L+ FL

– 3L+ MCL

– 3L+ MZL

EMPLICITI + POMALYST/IMNOVID

– RRMM

EMPLICITI + REVLIMID

– RRMM

IDHIFA

– R/R AML

INREBIC

– MF

ONUREG

– Post-Induction AML Continued Treatment/Maintenance

OPDIVO*

– R/R cHL

POMALYST/IMNOVID

– RRMM

– AIDS related Kaposi Sarcoma

– HIV-negative Kaposi Sarcoma

REBLOZYL*

– TD Beta-Thalassemia Associated Anemia

– MDS RS or MDS/MPN-RS-T Adult Patients and Previously Treated with ESA

– MDS Associated Anemia in ESA naïve patients who may require RBC Transfusion

REVLIMID

– MCL

– MDS

– MM

– FL

– MZL

– R/R T-Cell Leukemia

SPRYCEL

– 1L CML

– Acute Lymphoblastic Leukemia with Resistance or Intolerance to Prior Therapy

– Refractory CML

Note: Above pipeline excludes clinical collaborations

* Development Partnerships: Anti-CCR8 + nivolumab, nivolumab + relatlimab HD, *OPDIVO*, *YERVOY*: Ono; BMS-986495: Prothena; *COBENFY (KarXT)*, *AUGTYRO*: Zai Lab; pumitamig (BNT327/BMS-986545): BioNTech; iza-bren: SystImmune; milvexian: Johnson & Johnson; obexelimab: Zenas BioPharma; *REBLOZYL*: Merck

Partner-run study

Development Portfolio by Therapeutic Area

Oncology

Phase I

Investigational Compounds**Anti-CCR8**

– Solid Tumors

BMS-986460

– Prostate Cancer

BMS-986482

– Solid Tumors

BMS-986488

– Solid Tumors

BMS-986500

– Solid Tumors

BMS-986506

– Solid Tumors

BMS-986517

– Solid Tumors

BMS-986523

– Solid Tumors

BMS-986525

– R/R SCLC

CD40xFAP Bispecific

– Solid Tumors

CEACAM5-TOPO1 ADC

– Solid Tumors

iza-bren⁺– 1L NSCLC[#]

– Metastatic NSCLC

– Solid Tumors[#]**navlimetostat (PRMT5 Inhibitor)**

– Solid Tumors

pumitamig⁺

– 1L HCC

– 1L RCC

RYZ101

– ES-SCLC

– HR+/HER2- Unresectable Metastatic Breast Cancer

RYZ401

– Solid Tumors

RYZ801

– HCC

WEE1 CELMoD

– Solid Tumors

Phase II

Additional Indications**OPDIVO QVANTIG + YERVOY⁺**

– 1L NSCLC

Investigational Compounds**pumitamig⁺**

– 1L Microsatellite Stable CRC

– 1L Gastric Cancer

– 2L NSCLC[#]**iza-bren⁺**

– 1L TNBC

– EGFR-mutated Post-TKI NSCLC

– Post-IO Metastatic Urothelial Cancer

navlimetostat (PRMT5 Inhibitor)

– 1L NSCLC

– 1L PDAC

– 2L NSCLC

Phase III

Additional Indications**KRAZATI**– 1L NSCLC PD-L1 \geq 50%

– 1L NSCLC

– 2L CRC

OPDIVO⁺

– Adjuvant HCC

– Peri-adjuvant MIUC

Investigational Compounds**AR LDD**

– mCRPC

atigotatug + nivolumab

– 1L ES-SCLC

nivolumab + relatlimab**HD⁺**– 1L NSCLC PD-L1 \geq 1%**pumitamig⁺**– 1L ES-SCLC[#]– 1L NSCLC[#]– 1L NSCLC PD-L1 \geq 50%– 1L TNBC[#]

– Stage III NSCLC

RYZ101

– 2L+ SSTR2+ GEP-NETs

Approved Indications

ABRAXANE

– 1L Metastatic Adenocarcinoma of the Pancreas

– Locally Advanced or Metastatic NSCLC

– Metastatic Breast Cancer

AUGTYRO⁺

– ROS1+ NSCLC

– NTRK-Positive Locally Advanced or Metastatic Solid Tumors

KRAZATI

– 2L+ KRASG12C-mutated Advanced NSCLC

– KRASG12C-mutated CRC after prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy

OPDIVO⁺

– Metastatic Melanoma

– 1L Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma

– 1L Metastatic Esophageal

– 1L MIUC cis-eligible

– Adjuvant Melanoma

– Adjuvant Urothelial Carcinoma

– Adjuvant Esophageal/Gastroesophageal

– Neoadjuvant NSCLC

– Perioperative NSCLC

– Previously treated advanced RCC

– Previously treated Gastric cancer

– Previously treated Metastatic Head & Neck

– Previously treated Metastatic MSI-High CRC

– Previously treated Metastatic NSCLC

– Previously treated Metastatic Urothelial Cancer

– Previously treated Metastatic Esophageal Cancer

OPDIVO QVANTIG– Indicated for subcutaneous use in most previously approved adult, solid tumor *Opdivo* indications**OPDIVO⁺ + cabozantinib**

– 1L Advanced RCC

OPDIVO⁺ + YERVOY⁺

– 1L Metastatic Melanoma

– 1L Mesothelioma

– 1L Metastatic NSCLC

– 1L Advanced RCC

– 1L+ MSI-High CRC

– 1L HCC

– Previously treated HCC

– 1L Esophageal

OPDUALAG

– 1L Melanoma

YERVOY⁺

– Adjuvant Melanoma

– Metastatic Melanoma

Immunology

Phase I

Investigational Compounds

BMS-986454

– RA

CD19 HD Allo CAR T

– Autoimmune Diseases

zola-cel (CD19-targeted NEX-T)

– Idiopathic Inflammatory Myopathies

– Rheumatoid Arthritis

Phase II

Investigational Compounds

zola-cel (CD19-targeted NEX-T)

– SLE

Phase III

Additional Indications

SOTYKTU

– PsA

– Sjögren's Disease

– SLE

Investigational Compounds

admilparant

– Idiopathic Pulmonary Fibrosis

– Progressive Pulmonary Fibrosis

obexelimab*

– IgG4-Related Disease

zola-cel (CD19-targeted NEX-T)

– Systemic Sclerosis

Approved Indications

ORENCIA

– Moderate-to-Severe JIA

– Psoriatic Arthritis

– Moderate-to-Severe RA

– Prophylaxis of Acute Graft versus Host Disease

SOTYKTU

– Adults with Moderate-to-Severe Plaque Psoriasis

ZEPOSIA

– Relapsing forms of Multiple Sclerosis

– Moderate-to-Severe UC

Cardiovascular

Phase II

Investigational Compounds

MYK-224

– Heart Failure with Preserved Ejection Fraction

Phase III

Investigational Compounds

milvexian*

– Atrial Fibrillation[#]

– Secondary Stroke Prevention[#]

Approved Indications

CAMZYOS

– Symptomatic NYHA Class II-III Obstructive Hypertrophic Cardiomyopathy

ELIQUIS

– Stroke Risk Reduction in Non-Valvular Atrial Fibrillation

– Treatment of Venous Thromboembolism and Risk Reduction after Initial Therapy

– Prophylaxis of Deep Vein Thrombosis after Hip or Knee Replacement Surgery

Neuroscience

Phase I

Investigational Compounds

BMS-986495*

– Neurodegenerative Diseases[#]

BMS-986521

– Neuropsychiatric Disorders

eIF2B Activator

– Alzheimer's Disease

KarXT Long-Acting Injectable

– Schizophrenia

TRPC4/5 Inhibitor

– Mood and Anxiety Disorders

zola-cel (CD19-targeted NEX-T)

– Multiple Sclerosis

– Myasthenia Gravis

Phase II

Investigational Compounds

Anti-MTBR Tau

– Alzheimer's Disease

FAAH/MAGL Dual Inhibitor

– Alzheimer's Disease Agitation

– Multiple Sclerosis Spasticity

Phase III

Additional Indications

COBENFY*

– Adjunctive Bipolar-I Mania

– Agitation in Alzheimer's Disease

– Alzheimer's Disease Cognition

– Bipolar-I Mania

– Pediatric Autism Irritability

– Psychosis in Alzheimer's Disease

Approved Indications

COBENFY*

– Adults with Schizophrenia